Binding of death receptor 3 (DR3) to intracellular TRADD and TRAF2 is independent of its natural ligand, TL1A
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag194 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Weiyong Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immunology Research Unit, Research and Development, Pfizer Inc, Cambridge, MA, United States. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Ligand Superfamily Member 15, Receptors, Tumor Necrosis Factor, Member 25, TNF Receptor-Associated Factor 2, TNF Receptor-Associated Death Domain Protein. Die Arbeit nennt 86 Literaturangaben.
Abstract (Originalsprache)
The TNF‑like cytokine TL1A is a key regulator of immune responses through engagement of its receptor, death receptor 3 (DR3), and has emerged as a therapeutic target in inflammatory diseases. Prevailing models propose that TL1A binding initiates recruitment of adaptor proteins to DR3, leading to downstream signaling. Here, we investigated proximal DR3 signaling events and found that the adaptor proteins TRADD and TRAF2 associate with DR3 independently of TL1A stimulation in both TF‑1 cells and primary human CD4+ T cells. In contrast, TL1A stimulation was strictly required for activation of NF‑κB signaling, including IκBα degradation and downstream ubiquitination events. These findings indicate that DR3 can exist in a preassembled adaptor complex prior to ligand engagement and suggest a revised model in which TL1A binding confers signaling competence rather than initiating adaptor recruitment. We propose a structurally informed, hypothesis‑generating model in which ligand engagement promotes higher‑order organization of prebound signaling components to enable downstream signal transduction. Together, our results refine current understanding of TL1A/DR3 signaling by decoupling adaptor assembly from ligand‑dependent signal activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammation and Immunology Research Unit, Research and Development, Pfizer Inc, Cambridge, MA, United States.
- Discovery Biology and Pharmacology, Medicine Design, Preclinical and Translational Sciences, Research and Development, Pfizer Inc, Groton, CT, United States.
ORCID-Profile: Fridrik J Karlsson
Zitieren
APA
Sun, W., Johnson, B. G., Veerasubramanian, P. K., Rockwell, K., Dickinson, T. A., Sommese, R. F., & Karlsson, F. J. (2026). Binding of death receptor 3 (DR3) to intracellular TRADD and TRAF2 is independent of its natural ligand, TL1A. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag194
Vancouver
Sun W, Johnson BG, Veerasubramanian PK, Rockwell K, Dickinson TA, Sommese RF, et al. Binding of death receptor 3 (DR3) to intracellular TRADD and TRAF2 is independent of its natural ligand, TL1A. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag194
BibTeX
@article{Sun2026,
author = {Sun, Weiyong and Johnson, Bryce G and Veerasubramanian, Praveen K and Rockwell, Kristin and Dickinson, Theresa A and Sommese, Ruth F and Karlsson, Fridrik J},
title = {Binding of death receptor 3 (DR3) to intracellular TRADD and TRAF2 is independent of its natural ligand, TL1A},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag194}
}
EUVIMED